We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY.
- Authors
Sehn, L. H.; Bartlett, N. L.; Matasar, M.; Schuster, S. J.; Assouline, S.; Giri, P.; Kuruvilla, J.; Shadman, M.; Cheah, C. Y.; Fay, K.; Ku, M.; Nastoupil, L.; Wei, M. C.; Yin, S.; To, I.; Hu, N.; Min, J.; Penuel, E.; Belousov, A.; Coimbra, A.
- Abstract
MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND >=2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVOTAL PHASE II STUDY B Introduction: b Mosunetuzumab (Mosun) is a CD20xCD3 T-cell engaging bispecific antibody that redirects T cells to eliminate malignant B cells. B Conclusion: b Fixed-duration Mosun monotherapy demonstrated a high CR rate at EOT in pts with I R i / I R i FL, with many pts remaining event-free 2 years after EOT.
- Subjects
FOLLICULAR lymphoma; CYTOKINE release syndrome; BONE marrow diseases
- Publication
Hematological Oncology, 2023, Vol 41, p122
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3163_83